Syndax Pharmaceuticals, Inc.

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 4, 2026, the Company granted inducement awards to purchase up to 213,500 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals remains on track, with Revuforj driving robust commercial growth and Niktimvo providing a secondary revenue stream. 3Q26 revenue surged 82% YoY to $83.3M, led by Revuforj's 90% YoY growth; operating losses narrowed despite rising R&D spend. Post-transplant maintenance trends could extend Revuforj treatment duration, offering upside if patient resumption rates increase, as management anticipates.

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 14, 2026, from 7:00–8:30 a.m. CT / 8:00–9:30 a.m.

– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax's scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings, including frontline, post-transplant maintenance, and MRD relapse – – Real-world data showcase compelling results in R/R NPM1m or KMT2Ar acute leukemia patients who received revumenib monotherapy or combination therapy –  – 5 accepted axatilimab abstracts, including long-term data that highlight the potential for prolonged clinical benefit with axatilimab in R/R cGVHD – – Company to host investor event and webcast on Monday, December 14, 2026, at 7:00 a.m. CT/8:00 a.m.